Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 24, 2015 - Issue 2
Submit an article Journal homepage
712
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluation

The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma

Jeffrey D AltenburgIndiana University School of Medicine, Department of Microbiology and Immunology, Indianapolis, IN, USA
, PhD &
Sherif S FaragIndiana University School of Medicine, Division of Hematology and Oncology, Department of Medicine, Walther Hall R3-C414, 980 West Walnut Street, Indianapolis, IN 46202, USA, [email protected];Indiana University School of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN, USA
, MD PhD
Pages 261-271 | Published online: 13 Dec 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Silvia Paola Corona & Daniele Generali. (2018) Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer. Drug Design, Development and Therapy 12, pages 321-330.
Read now
Moataz Ehab & Mohamad Elbaz. (2016) Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy 8, pages 83-91.
Read now

Articles from other publishers (12)

Isabella Mengich, Sheerien Rajput, Riyat Malkit, Zahir Moloo, Elizabeth Kagotho, El-Nasir Lalani & Anne Mwirigi. (2023) Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya. Frontiers in Medicine 10.
Crossref
Chonglv Feng, Zhe Cheng, Zhijian Xu, Ye Tian, Huimin Tian, Fan Liu, Damin Luo & Yanhai Wang. (2022) EmCyclinD-EmCDK4/6 complex is involved in the host EGF-mediated proliferation of Echinococcus multilocularis germinative cells via the EGFR-ERK pathway. Frontiers in Microbiology 13.
Crossref
Darren Pan & Joshua Richter. (2022) Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Frontiers in Oncology 11.
Crossref
Anna Richter, Nina Schoenwaelder, Sina Sender, Christian Junghanss & Claudia Maletzki. (2021) Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. Cancers 13:10, pages 2497.
Crossref
Min Zhao, Min Hu, Yong Chen, Heyi Liu, Yulu Chen, Bin Liu & Baijun Fang. (2021) Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. Biochemical and Biophysical Research Communications 549, pages 150-156.
Crossref
Jian Zhang, Nong Yang, Dongmei Ji, Weina Shen, Wenhua Li, Rubing Han, Ning Wang, Haoxun Tao, Sonya C. Chapman, Amanda K. Sykes, Wanli Zhang & Xichun Hu. (2021) A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. Targeted Oncology 16:2, pages 177-187.
Crossref
D.M. Fernández-Aroca, O. Roche, S. Sabater, R. Pascual-Serra, M. Ortega-Muelas, I. Sánchez Pérez, B. Belandia, M.J. Ruiz-Hidalgo & R. Sánchez-Prieto. (2019) P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. Cancer Letters 451, pages 23-33.
Crossref
Maria Pia Abruzzese, Maria Teresa Bilotta, Cinzia Fionda, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rosa Molfetta, Rossella Paolini, Angela Santoni & Marco Cippitelli. (2019) The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death & Disease 10:4.
Crossref
Cédric Alande, Mathilde Fénélon & Jean-Christophe Fricain. (2018) Oral ulcers in patients treated with palbociclib: a case report. Journal of Oral Medicine and Oral Surgery 24:2, pages 60-62.
Crossref
Xichun Hu, Wei Huang & Minhao Fan. (2017) Emerging therapies for breast cancer. Journal of Hematology & Oncology 10:1.
Crossref
Silvia Paola Corona, Andrea Ravelli, Daniele Cretella, Maria Rosa Cappelletti, Laura Zanotti, Martina Dester, Angela Gobbi, Pier Giorgio Petronini & Daniele Generali. (2017) CDK4/6 inhibitors in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology 112, pages 208-214.
Crossref
Hanley N. Abramson. (2016) Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget 7:49, pages 81926-81968.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.